PHAR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Pharming Group (PHAR)

Pharming Group missed Q2 2026 consensus revenue estimates and shares dropped 22% in a single session. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR investors who lost money.

NEW YORK--(BUSINESS WIRE)--A 22% single-session drop hit Pharming Group (PHAR) shares today after the Company reported Q2 2026 revenue of $90.2 million -- a 3% year-over-year decline against analyst consensus of roughly $419 million for the full year. If you lost money on PHAR, click here to submit your losses for review. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

The miss came from the Company's legacy product. RUCONEST sales fell 10% year-over-year to $72.3 million. Although Joenja revenue rose 40% to $17.9 million -- the growth was not enough to offset the decline in RUCONEST. Diluted EPS came in at $0.002, down from $0.006 in the prior-year quarter.

Alongside the results, Pharming reduced its full-year 2026 revenue outlook to $375 million to $395 million, from a prior range of $405 million to $425 million. The revised midpoint of $385 million was approximately $30 million below the previous midpoint and below analyst expectations.

Shareholders who purchased PHAR and suffered a loss are encouraged to have their claim evaluated at no cost. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the PHAR Investigation

Q: How much did PHAR stock drop? A: Shares fell approximately 22% on July 30, 2026 after the Company reported Q2 2026 revenue of $90.2 million and reduced its full-year 2026 revenue outlook to $375 million to $395 million. Investors who purchased shares and suffered losses may be eligible to seek recovery.

Q: What is the PHAR securities investigation about? A: A securities investigation is pending concerning Pharming Group (PHAR) regarding potentially materially false or misleading statements. Shares fell approximately 22% after the Company disclosed a Q2 revenue decline and a reduced full-year outlook, causing losses for shareholders.

Q: Who is eligible to participate in the PHAR investigation? A: Investors who purchased PHAR stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: What do PHAR investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [e-mail] or [phone].

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my PHAR shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought PHAR and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to participate. Securities investigations and any resulting actions are generally handled on a contingency basis -- no retainer and no out-of-pocket costs.

Q: What if I live outside the United States? A: U.S. securities investigations generally cover purchases on U.S. exchanges regardless of the investor's country of residence.

Attorney Advertising. Prior results do not guarantee similar outcomes.